Cantor Fitzgerald Analysts Lower Earnings Estimates for IDYA

Key Points

• Cantor Fitzgerald has lowered its FY2025 EPS estimates for IDEAYA Biosciences from ($2.62) to ($3.00), while the current consensus estimate is ($3.07) per share.
• The stock received a mix of ratings from analysts, with Goldman Sachs upgrading it to "hold" and setting a price target of $25.00, while JPMorgan Chase raised their target from $66.00 to $72.00, giving it an "overweight" rating.
• Shares of IDEAYA Biosciences opened at $22.41, with a market cap of $1.96 billion and a 52-week price range between $13.45 and $40.74.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for IDEAYA Biosciences in a research note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($3.00) per share for the year, down from their previous estimate of ($2.62). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Cantor Fitzgerald also issued estimates for IDEAYA Biosciences' FY2026 earnings at ($2.68) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. During the same period in the previous year, the business earned ($0.68) EPS. The company's revenue for the quarter was up NaN% on a year-over-year basis.

Other research analysts also recently issued reports about the stock. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a research note on Thursday, July 10th. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and reduced their price objective for the company from $57.00 to $30.00 in a research note on Wednesday, July 9th. JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a research note on Monday, July 28th. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price objective on the stock. Finally, TD Cowen started coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $48.09.

IDEAYA Biosciences Trading Up 2.9%

NASDAQ IDYA traded up $0.67 during trading hours on Friday, reaching $23.51. 391,798 shares of the company traded hands, compared to its average volume of 1,150,507. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $40.74. The stock has a market capitalization of $2.06 billion, a PE ratio of -6.22 and a beta of 0.09. The company has a 50 day moving average of $22.51 and a two-hundred day moving average of $20.34.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IDYA. Janus Henderson Group PLC grew its position in IDEAYA Biosciences by 13.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after purchasing an additional 695,263 shares during the last quarter. Millennium Management LLC grew its position in IDEAYA Biosciences by 345.2% in the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company's stock worth $8,970,000 after purchasing an additional 424,625 shares during the last quarter. Ensign Peak Advisors Inc grew its position in IDEAYA Biosciences by 126.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company's stock worth $15,593,000 after purchasing an additional 414,189 shares during the last quarter. MPM Bioimpact LLC bought a new position in IDEAYA Biosciences in the 4th quarter worth about $10,641,000. Finally, FMR LLC grew its position in IDEAYA Biosciences by 2.6% in the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after purchasing an additional 327,498 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.